Post-SRS complications in patients with VS
| Post-SRS Complication/Adverse Effects | Reported Incidence | Risk/Prognostic Factors |
|---|---|---|
| Vertigo and disequilibrium | 1%–2% | Marginal dose <13 Gy; larger tumors; female sex associated with worse outcomes |
| Facial nerve dysfunction | <1% | Younger patients, smaller tumors <1.5 cm3, and radiation dose <13 Gy associated with better outcomes |
| Trigeminal nerve dysfunction | 3% at 5 years | Total dose >13 Gy; brainstem dose >10 Gy; larger tumor volume associated with worse outcomes |
| Worsening hearing loss | 21%–59% at 5 years | Cochlear dose >4 Gy; marginal dose >13 Gy associated with worse outcomes |
| Hydrocephalus | 2%–3% | Older than 60 years of age; female sex; larger tumors associated with worse outcomes |
| Malignant transformation | <0.04% at 15 years | Underlying neurofibromatosis associated with increased incidence |